The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 14, 2025

Filed:

Dec. 06, 2019
Applicant:

Wuhan Healthgen Biotechnology Corp, Wuhan, CN;

Inventors:

Daichang Yang, Wuhan, CN;

Quan Zhan, Wuhan, CN;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 1/18 (2006.01); B01D 15/20 (2006.01); B01D 15/36 (2006.01); B01D 15/42 (2006.01); C07K 1/14 (2006.01); C07K 1/34 (2006.01); C07K 1/36 (2006.01); C07K 14/78 (2006.01); C12N 15/82 (2006.01);
U.S. Cl.
CPC ...
C07K 1/18 (2013.01); B01D 15/203 (2013.01); B01D 15/362 (2013.01); B01D 15/363 (2013.01); B01D 15/426 (2013.01); C07K 1/145 (2013.01); C07K 1/34 (2013.01); C07K 1/36 (2013.01); C07K 14/78 (2013.01); C12N 15/8257 (2013.01);
Abstract

Disclosed is a chromatographic method for separating and purifying a recombinant human fibronectin from a genetically engineered rice seed that expresses the human fibronectin. In the method, the genetically engineered rice seed is milled, mixed with an extraction buffer, and then filtered to obtain a crude extract comprising the recombinant human fibronectin; the crude extract comprising the recombinant human fibronectin is subjected to cation exchange chromatography, so as to perform primary separation and purification, thereby obtaining a primary product comprising the recombinant human fibronectin; and the primary product is subjected to anion exchange chromatography so as to perform final separation and purification to obtain the recombinant human fibronectin as a target substance. The method is low cost and easily utilized on an industrial scale. The obtained OsrhFn target substance has a SEC-HPLC purity greater than 95% with excellent bioactivity.


Find Patent Forward Citations

Loading…